Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12610000067077
ACTRN12610000067077
Completed
Phase 1

Safety and efficacy of cell immunotherapy to treat hepatitis C virus (HCV) infection

Eric J Gowans0 sites15 target enrollmentJanuary 20, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHepatitis C virus infectionOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune system

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hepatitis C virus infection
Sponsor
Eric J Gowans
Enrollment
15
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 20, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Eric J Gowans

Eligibility Criteria

Inclusion Criteria

  • •HCV ribonuclei acid (RNA) positive for \>6 months.
  • •Previously failed interferon\-based therapy
  • •Infected with genotype 1 virus.

Exclusion Criteria

  • •Hepatitis B virus (HBV)\-positive
  • •Human immunodeficiency virus (HIV)\-positive
  • •Evidence of autoimmunity

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Investigate the safety and efficacy of small cell lung cancer,Kidney cancer and Primary liver cancer immunotherapyHistopathologically confirmed small cell lung cancer (SCLC)Histopathologically confirmed Kidney cancerHistopathologically confirmed Liver cancer
ACTRN12618001337268The First Teaching Hospital, Inner Mongolia Medical University50
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2012-002554-23-ITOCTAPHARMA AG108
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2012-002554-23-PLOCTAPHARMA AG108
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 18.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2012-002554-23-HROCTAPHARMA AG108
Active, not recruiting
Phase 1
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2012-002554-23-PTOCTAPHARMA AG100